Skip to main content
Equibles
TENX logo

TENX · Tenax Therapeutics, Inc. · Metrics

Track TENX — free

Use TENX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TENX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.72 +0.08 (+4.88%) At close · Oct 27
Russell 2000 member Rebalance outlook locked
Market Cap
$61.94M
Shares
37.42M
Volume · Oct 27 1.67M Avg daily vol (3M) 5.61M

TENX metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.72
Market cap
$61.94M

Price action

20 metrics
Price change (1W)
+7.9%
Price change (30D)
-11.4%
Price change (3M)
-89.9%
Price change (6M)
-89.1%
Price change (YTD)
-86.5%
Price change (1Y)
-77.8%
Trailing year
Price change (5Y)
—
52-week high
$18.32
52-week low
$1.36
Change from 52-week high
-91.0%
Change from 52-week low
+20.6%
Annualized volatility
127.8%
Annualized volatility (3M)
206.2%
Beta
1.0
RSI (14D)
37.6
Price vs SMA 50
-10.9%
Price vs SMA 200
-84.1%
Avg volume (3M)
5.62M
Relative volume
0.2
Average dollar volume
$13.38M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
37.42M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.5
reciprocal yield 182.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-104.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$68.61M
Net income (TTM)
−$64.86M
Trailing 12 months
Diluted EPS (TTM)
$-1.49
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.56
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.47
Operating cash flow per diluted share (TTM)
$-1.04
Free cash flow per diluted share (TTM)
$-894.48
Capital expenditures per diluted share (TTM)
$0.39
R&D per diluted share (TTM)
$1.03
Stock compensation per diluted share (TTM)
$0.39
Book value per share
$10.42

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+28.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-57.1%
Return on assets
-53.3%
Debt / equity
0.0
Current ratio
15.1
EBITDA (TTM)
−$19.49M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$118.00M
Latest balance sheet
Cash & equivalents
$118.00M
Total assets
$121.66M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$46.03M
Capital expenditures (TTM)
—
R&D (TTM)
$45.26M
SG&A (TTM)
—
Stock compensation (TTM)
$16.58M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
115
13F filer change QoQ
+34
Institutional ownership
87.5%
Conviction holders (share of 13F filers)
3.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+21.9%
Holder tenure
4.2
Price vs estimated holder cost
+24.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.3%

Short interest

3 metrics
Short interest
19.3%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
$132,828
Insider-sentiment score
89 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 34956 CUSIP 88032L605 13F (30d) 8 filings 8 filers Visit website Investor relations